Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. Introduction: Life as Pathos and Praxis ...
In a single news cycle, Pathos AI announced two simultaneous drug licensing agreements worth up to $2.3 billion in combined milestones — and disclosed that it is targeting a $300 million Series E ...
While teaching a class on intelligence and analysis last year, I asked my graduate students why the media’s shocking picture of the drowned Syrian boy seemed to have such an incredible effect on ...
Iker Huerga, Pathos AI's chief executive. Pathos AI has added to its pipeline of cancer drugs by licensing a bispecific antibody-drug conjugate (ADC) for solid tumours from China's Alphamab in a deal ...
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief ...
Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and trial design. NEW YORK--(BUSINESS WIRE)--Pathos AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results